Eyepoint Pharmac Stock Price, News & Analysis

EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. Jay S. Duker, M.D., the company's President and CEO, will engage in a fireside chat scheduled for Thursday, February 6, 2025, at 9:30 a.m. ET.

Interested parties can access the webcast and subsequent replay through the Investors section of EyePoint's website at www.eyepointpharma.com.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to four new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee on January 15, 2025, allow the purchase of up to 30,300 shares of common stock at an exercise price of $7.69 per share, matching the closing price on the grant date.

The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first anniversary, with the remaining shares vesting in equal monthly installments over the following three years. Vesting is contingent upon continued employment with EyePoint.

EyePoint Pharmaceuticals (NASDAQ: EYPT) provided updates on its lead product candidate, DURAVYU™, and key milestones for 2025. The company reported strong enrollment in its Phase 3 wet AMD clinical trials, with LUGANO being one-third enrolled and LUCIA ahead of schedule. Both trials are expected to complete enrollment in H2 2025, with topline data in 2026.

The company highlighted positive interim results from the Phase 2 VERONA trial in DME, with full data expected in Q1 2025. DURAVYU demonstrated meaningful improvements in patients with active DME, showing CST improvement of 68.1 microns and BCVA gain of +8.9 letters vs. baseline.

Notable corporate updates include the appointment of Dr. Reginald J. Sanders to the Board and the opening of a new 40,000+ square-foot manufacturing facility in Northbridge, MA. The company reported approximately $370 million in cash and investments as of December 31, 2024, with runway extending into 2027.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has appointed Dr. Reginald J. Sanders, a prominent retina specialist, to its Board of Directors. Dr. Sanders, the most recent President of the American Society of Retina Specialists, brings extensive clinical and business development experience in retinal diseases.

The appointment comes at a important time as EyePoint advances its global phase 3 pivotal trials for wet AMD and following positive interim data from its Phase 2 trial in diabetic macular edema. Dr. Sanders has significant experience as a principal investigator, including work on Lucentis® for wet AMD treatment, and has published over 50 papers. He currently serves as a board member of Prism Vision Group and is affiliated with the Retina Group of Washington, which he helped build into the largest retinal specialist practice in the United States.

EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jay S. Duker, M.D., the company's President and CEO, will deliver a presentation on January 14, 2025 at 2:15 p.m. PT/5:15 p.m. ET in San Francisco. Investors and interested parties can access the presentation webcast and replay through the Investors section of EyePoint's website.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to six new employees as inducement awards. The grants, approved by the Compensation Committee on December 13, 2024, include options to purchase up to 54,600 shares of common stock at an exercise price of $7.46 per share. These options have a ten-year term and follow a four-year vesting schedule, with 25% vesting after the first year and the remainder vesting in equal monthly installments over the following three years. The awards were made outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

EyePoint Pharmaceuticals (NASDAQ: EYPT) has initiated dosing in LUCIA, its second global Phase 3 clinical trial of DURAVYU for wet age-related macular degeneration (wet AMD) treatment. DURAVYU delivers vorolanib through the proprietary Durasert E™ platform for sustained intraocular delivery.

The LUCIA and LUGANO Phase 3 trials will each enroll approximately 400 patients globally, comparing a 2.7mg DURAVYU dose to aflibercept. DURAVYU will be administered every six months, starting at month two. The primary endpoint is the average change in best corrected visual acuity at weeks 52 and 56 versus baseline.

With over 240 global sites committed and strong patient interest, EyePoint expects topline data in 2026. These trials are notable as the first and only sustained release wet AMD pivotal program evaluating re-dosing in both studies.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to four new employees as inducement awards. The grants, approved by the Compensation Committee, include options to purchase up to 23,600 shares at an exercise price of $9.17 per share, based on the closing price on November 15, 2024. The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments over the following three years, subject to continued employment.

EyePoint Pharmaceuticals reported Q3 2024 financial results and corporate updates. Key highlights include positive interim data for DURAVYU 2.7mg in DME showing +8.9 letters BCVA improvement and -68 microns CST reduction at 16 weeks. The company initiated Phase 3 LUGANO trial for wet AMD and completed a $161M equity financing. Q3 revenue was $10.5M, down from $15.2M in Q3 2023. Net loss increased to $29.4M ($0.54 per share) from $12.6M ($0.33 per share) year-over-year. Cash position stands at $253.8M, with runway extended into 2027 following the recent financing.